Danaher(DHR) Prnewswire·2024-07-23 10:00Key Points - Danaher Corporation reported net earnings of 1.22 per diluted common share, with non-GAAP adjusted diluted net earnings per common share at 5.7 billion, with non-GAAP core revenue down 3.5% [1][11] - Operating cash flow was reported at 1.1 billion [1][12] - The company expressed satisfaction with the performance of its bioprocessing business and Cepheid, indicating market share gains in molecular testing [1][3] - Danaher anticipates low-single digit declines in non-GAAP core revenue for both the third quarter and full year 2024 [1][11] Financial Performance - For the three-month period ended June 28, 2024, total sales were 5.912 billion in the same period last year [5][11] - Gross profit for the quarter was 1.168 billion [6][11] - The company reported a year-over-year decline in net earnings from continuing operations, which was 920 million in the previous year [5][11] Segment Performance - The biotechnology segment experienced a sales decline of 9.0%, while life sciences and diagnostics segments saw declines of 1.5% and growth of 1.5%, respectively [11] - Core sales growth was reported as a decline of 3.5% for the three-month period, with a forecasted decline of low-single digits for the upcoming periods [11][12] Cash Flow Analysis - Total cash flow from continuing operations was 1.646 billion year-over-year [12] - Free cash flow from continuing operations was reported at 1.319 billion in the previous year [12]